Tirzepatide | Research Grade | COA Verified

Description

Research area: Dual incretin-receptor signaling and metabolic research

Product Description

Tirzepatide is a synthetic 39-amino-acid linear peptide engineered as a dual agonist of the GIP and GLP-1 incretin receptors. Based on the GIP sequence and modified to bind both receptor systems, it carries a C20 fatty-diacid moiety attached via a linker, which promotes albumin binding and confers an extended in-vitro and in-vivo half-life. This single molecule reproduces incretin signaling at two targets at once, a design distinguishing it from selective GLP-1 receptor agonists. In research it is characterized as an imbalanced, biased co-agonist, engaging the GIP receptor strongly while showing signaling bias at the GLP-1 receptor.

Mechanism & Research Context

Tirzepatide activates two class B G-protein-coupled receptors, GIPR and GLP-1R, both coupling to Gs to raise cAMP in pancreatic and other cell types and stimulating glucose-dependent insulin secretion in models. Pharmacological studies describe it as imbalanced, engaging GIPR more fully, and biased at GLP-1R toward cAMP generation over beta-arrestin recruitment. The fatty-diacid modification extends exposure via albumin binding. Preclinical work uses it to dissect incretin cross-talk, receptor trafficking, and metabolic signaling in cell and animal systems.

Research Applications

• Dual GIPR/GLP-1R binding and cAMP-signaling assays
• Biased-agonism and beta-arrestin-recruitment studies
• Glucose-dependent insulin-secretion models in vitro
• Metabolic and hepatic-steatosis animal-model research
• Albumin-binding and peptide-half-life investigations

Storage & Handling

• Store sealed vials in a cool, dark place for short-term storage and frozen for long-term storage.
• After reconstitution, refrigerate and protect from light and heat.
• Avoid repeated freeze-thaw cycles; handle using standard laboratory safety and aseptic technique.

Product Specifications

• Compound class: Fatty-acid-modified 39-amino-acid dual GIP/GLP-1 receptor co-agonist peptide
• Form: Lyophilized powder
• Purity: ≥ 99% (HPLC verified)
• Appearance: White to off-white powder
• Third-party tested: Yes — Certificate of Analysis (COA) on this product page

Quality & Third-Party Testing

Every batch of Tirzepatide is independently third-party tested in the USA for identity and purity, with a Certificate of Analysis (COA) available on this product page.

Compliance Notice

Tirzepatide is for research use only. It is not intended for human or veterinary use and has not been evaluated by the FDA. By purchasing, the buyer represents and warrants that it will be used solely for in-vitro laboratory research.